Table 1 Demographic information and urine BMP levels in study participants.

From: Elevated urine BMP phospholipids in LRRK2 and VPS35 mutation carriers with and without Parkinson’s disease

 

Control

iPD

LRRK2 G2019S

LRRK2 R1441G/C

VPS35 D620N

GBA

p-value

N = 22

N = 31

N = 18

N = 13

N = 10

N = 10

Age

55

65.5

59.5

65

62.5

61

<0.001a

Median (range)

(24, 71)

(45, 88)

(42, 81)

(50, 83)

(29, 76)

(49, 64)

Sex

11/11

15/16

11/7

6/7

7/3

3/7

0.5b

Female/male

PD status

--

--

11/7

7/6

9/1

10/0

--

PD/NMC

Disease duration

--

6

6

9

15

5

0.2a

Median (range)

(1, 17)

(1, 22)

(6, 20)

(1, 21)

(1, 21)

Total di-18:1-BMP

3.66

6.48*

13.43****

9.57**

15.97****

2.56

<0.001a

Median (range)

(0.72, 8.54)

(1.48, 38.88)

(3.30, 42.56)

(2.70, 34.68)

(6.71, 55.37)

(0.80, 45.53)

2,2’-di-18:1-BMP

2.04

4.58**

11.59****

4.68**

13.69****

1.58 (0.59, 21.59)

<0.001a

Median (range)

(0.52, 5.60)

(1.01, 34.58)

(2.86, 33.59)

(1.55, 29.59)

(4.54, 46.10)

Total 22:6-BMP

8.33

12.84

43.52****

28.11***

29.19***

9.66 (3.97, 34.21)

<0.001a

Median (range)

(2.18, 41.14)

(3.28, 104.92)

(6.98, 321.98)

(7.94, 81.34)

(15.51, 162.36)

2,2’-di-22:6-BMP

4.83

9.86*

33.43****

21.27***

22.61***

5.93 (2.81, 21.31)

<0.001a

Median (range)

(1.47, 19.59)

(2.17, 60.15)

(5.61, 153.74)

(4.35, 47.35)

(8.98, 126.35)

  1. Values are median of the measured BMP normalized to the creatinine amount (ng/mg creatinine).
  2. GBA group includes carriers of the following variants: c.762-1 G > C, het.del-from exon3, p.Pro138Leufs*62, p.Thr408Met, p.Ser212* and p.Thr408Met, p.Glu365Lys, p.Asn409Ser.
  3. NMC non-manifesting carrier.
  4. Values significantly different from Control group: *p < 0.05; **p < 0.01; ***p < 0.001, ****p < 0.0001, Dunn’s multiple comparison test.
  5. aKruskal–Wallis rank sum test.
  6. bFisher’s exact test.
Back to article page